Aridis Pharmaceuticals Inc (ARDS)

$0.00 +0.00 (900.00%)
Market Cap 11,000.00
Revenue (ttm) 3.09M
Net Income (ttm) -30.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -982.85%
Debt to Equity Ratio 0.00
Volume 34,500
Avg Vol 47,204
Day's Range N/A - N/A
Shares Out 53.32M
Stochastic %K 86%
Beta 34.71
Analysts Strong Buy
Price Target $2.00

Company Profile

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquir...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 385 1742
Fax: 408 356 9548
Address:
983 University Avenue, Building B, Los Gatos, United States
Bigos
Bigos Nov. 4 at 5:36 PM
$ARDS Looks like Vu probably cashed out, and moved to Germany, to enjoy retirement. He doesn't appear to be doing much with the company over the past year.
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Nov. 3 at 3:29 PM
$ARDS Assuming there was any interest in the company's technology, at this point, they would be negotiating from a point of desperation. Nothing good will happen from here.
0 · Reply
BostonDave
BostonDave Oct. 15 at 11:46 AM
$ARDS sent one last email to their inquiry email address asking for update. Last time Vu responded. Let’s see if there is a response. Otherwise I will harvest the tax loss.
2 · Reply
Bigos
Bigos Oct. 14 at 8:37 PM
$ARDS Yep. Well said. Unfortunately ARDS has a CEO that has failed to provide any actual updates, all while stringing investors along for years. If this company's tech had any value, he would have sold it by now. No pharma appears to be interested in it.
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Oct. 14 at 6:15 PM
$ARDS Pretty funny that the guy who's been predicting a big buyout for 3+ years is talking about posts not aging well. Talk about a lack of self-awareness.
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Oct. 14 at 3:55 PM
$ARDS Dude...STFU already.
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Oct. 14 at 3:52 PM
$ARDS Biotech investment is risky. CEOs make you feel special if you see the potential. Reality is, data is cultivated and presented in a manner that is designed to sell shares. Management is critical. If you have a bum for a CEO with no significant biotech community members on the BOD...run.
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 11 at 8:46 AM
$ARDS is merger monday still a thing? I hope. Please end this nightmare here.
0 · Reply
NoseToTheGrindstone
NoseToTheGrindstone Oct. 10 at 5:07 PM
$ARDS Looks like the most shares traded here in a single day in over a year.
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 10 at 4:39 PM
$ARDS already 800000 shares traded. Something going on?
0 · Reply
Latest News on ARDS
No data available.
Bigos
Bigos Nov. 4 at 5:36 PM
$ARDS Looks like Vu probably cashed out, and moved to Germany, to enjoy retirement. He doesn't appear to be doing much with the company over the past year.
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Nov. 3 at 3:29 PM
$ARDS Assuming there was any interest in the company's technology, at this point, they would be negotiating from a point of desperation. Nothing good will happen from here.
0 · Reply
BostonDave
BostonDave Oct. 15 at 11:46 AM
$ARDS sent one last email to their inquiry email address asking for update. Last time Vu responded. Let’s see if there is a response. Otherwise I will harvest the tax loss.
2 · Reply
Bigos
Bigos Oct. 14 at 8:37 PM
$ARDS Yep. Well said. Unfortunately ARDS has a CEO that has failed to provide any actual updates, all while stringing investors along for years. If this company's tech had any value, he would have sold it by now. No pharma appears to be interested in it.
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Oct. 14 at 6:15 PM
$ARDS Pretty funny that the guy who's been predicting a big buyout for 3+ years is talking about posts not aging well. Talk about a lack of self-awareness.
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Oct. 14 at 3:55 PM
$ARDS Dude...STFU already.
1 · Reply
ReturnOfEsquire
ReturnOfEsquire Oct. 14 at 3:52 PM
$ARDS Biotech investment is risky. CEOs make you feel special if you see the potential. Reality is, data is cultivated and presented in a manner that is designed to sell shares. Management is critical. If you have a bum for a CEO with no significant biotech community members on the BOD...run.
0 · Reply
Phaaisatroll
Phaaisatroll Oct. 11 at 8:46 AM
$ARDS is merger monday still a thing? I hope. Please end this nightmare here.
0 · Reply
NoseToTheGrindstone
NoseToTheGrindstone Oct. 10 at 5:07 PM
$ARDS Looks like the most shares traded here in a single day in over a year.
1 · Reply
Phaaisatroll
Phaaisatroll Oct. 10 at 4:39 PM
$ARDS already 800000 shares traded. Something going on?
0 · Reply
Bigos
Bigos Oct. 2 at 8:53 PM
$ARDS Who here still remembers @Phaaisatroll telling everyone on here that he was predicting that we'd all be "getting a very nice Christmas present in 2024", because he had insider knowledge that a "buyout by AstraZeneca" was imminent? He forgot to tell Vu about this, apparently....
1 · Reply
Phaaisatroll
Phaaisatroll Sep. 18 at 12:25 PM
$ARDS something has to happen at some point. Aridis can't do anything right now and management can't even get paid if they don't have any money. So why dragging this out that long? Sell everything and move on or declare bankruptcy and move on. At least the fact that they still didn't declare bankruptcy means they are trying to go for option one or other deals and not for the bankruptcy option.
0 · Reply
Shanenobody
Shanenobody Sep. 15 at 7:32 PM
$ARDS 250,000 shares traded today at .0013?
4 · Reply
Flibble
Flibble Sep. 15 at 5:20 AM
$ARDS Friday was another 100k volume day. Weird.
1 · Reply
Shanenobody
Shanenobody Sep. 8 at 11:30 PM
$ARDS What's going on with this stock? Today's volume is 102,250. I don't recall this kind of volume since they went on the expert market. I'm not saying it hasn't happened, I just don't recall it happening. To make this a little more puzzling, the price has gone up twice in the last week as well.
1 · Reply
ChiefStockTraderJr
ChiefStockTraderJr Sep. 2 at 5:13 AM
$ARDS 12%??? That's it folks. Put a fork in it. Game over man. Game over. Done. Finished. We LOST all our money invested in this stock. No future for it left. Too bad. I was hoping for so much more. I gambled and I LOST it all.
1 · Reply
Bigos
Bigos Aug. 22 at 4:14 PM
$ARDS Per the article, in the Phase III clinical trial the cure rate only increased by 12%, mostly in elderly adults. 12% --- no wonder no big pharma wants to buy this company, and Vu has gone silent.
0 · Reply
ReturnOfEsquire
ReturnOfEsquire Aug. 21 at 2:17 PM
$ARDS Since dumbass can't use Google translate https://news-gbimonthly-com.translate.goog/tw/audiovisual/show.php?num=78887&page=2&kind=11&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en-US&_x_tr_pto=wapp
2 · Reply
Phaaisatroll
Phaaisatroll Aug. 10 at 9:08 AM
$ARDS a bit from the conference where Vu went recently. https://reurl.cc/bmlzel
2 · Reply
ReturnOfEsquire
ReturnOfEsquire Aug. 7 at 2:57 AM
$ARDS I could easily drive over to the company's office to see if it's dark, but I enjoy watching @Phaaisatroll slowly lose his mind...
3 · Reply
ReturnOfEsquire
ReturnOfEsquire Aug. 5 at 5:48 PM
$ARDS Is it true Vu Troung translates to "So long, suckers!"?
2 · Reply
Phaaisatroll
Phaaisatroll Jul. 27 at 10:14 PM
$ARDS Vu Truong was at a conference in Taipei. Hopefully this doesn't mean that he already left the country.
3 · Reply